{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000004","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.637244+00:00","generated_at":"2026-06-20T17:36:37.281197+00:00","sec_items":["2.02","2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Emergent BioSolutions preliminary 2022 rev down 38%, adj net loss $70-90M, cuts 5% workforce, exec departures","bullets":["Preliminary 2022 revenue $1.1-1.12B, down 38% YoY; adj net loss $70-90M; adj EBITDA $20-40M.","Restructuring eliminates 132 roles (5% workforce) with $9-11M charges in Q1 2023; annual savings >$60M.","EVP Katy Strei (CPO) and EVP Atul Saran (CSDO) to depart March 17; Michelle Pepin promoted to CHRO.","Paul Williams appointed SVP Products Business leading MCM and NARCAN; Kelly Warfield leads new S&D function.","2023 financial outlook deferred to late February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000004","json":"https://secwatch.observer/filing/0001367644-23-000004.json","markdown":"https://secwatch.observer/filing/0001367644-23-000004.md","text":"https://secwatch.observer/filing/0001367644-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/ebs-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:36:37.281197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40b018fe6aad8d09b38922a1df52ffbb3e56dba6","claim":"Emergent BioSolutions Inc. reported full-year 2022 results: revenue $1,100-$1,120 million, net income $(210)-$(190) million.","evidence_excerpt":"Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Revenue","value":"$1,100-$1,120 million"},{"label":"Net income","value":"$(210)-$(190) million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"005b04e664","claim":"Paul Williams was appointed as Senior Vice President Products Business at Emergent BioSolutions Inc..","evidence_excerpt":"The Company also announced the appointment of Paul Williams as the Company’s Senior Vice President Products Business, reporting to the Company’s CEO, Robert Kramer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President Products Business"}],"fact_type":"executive_change"},{"claim_id":"0db9d8e960","claim":"Atul Saran departed as Chief Strategy and Development Officer at Emergent BioSolutions Inc..","evidence_excerpt":"Atul Saran, the Company’s Chief Strategy and Development Officer, will cease employment with the Company on or about March 17, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will cease employment"},{"label":"Role","value":"Chief Strategy and Development Officer"}],"fact_type":"executive_change"},{"claim_id":"7e72dc64f0029d66e7659d89e06bbe423d93c300","claim":"Emergent BioSolutions Inc. announced a restructuring with charges of $9.0M to $11.0M affecting the Company (approximately 5 percent).","evidence_excerpt":"On January 9, 2023, the Company also announced an organizational restructuring plan (the “Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. The Plan includes a reduction of the Company’s current workforce by approximately 5 percent.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$9.0M to $11.0M"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"approximately 5 percent"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}